ULBP1, human recombinant protein
NKG2D ligand 1, UL16 binding protein 1, RAET1I, N2DL-1, N2DL1, NKG2D ligand 1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9BZM6 |
---|---|
Concentration | 0.5 |
Calculated MW | 25 kDa (216 aa, 26-216 aa + His Tag), confirmed by MALDI-TOF. |
Gene ID | 80329 |
---|---|
Gene Symbol | ULBP1 |
Other Names | NKG2D ligand 1, UL16 binding protein 1, RAET1I, N2DL-1, N2DL1, NKG2D ligand 1 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥90% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Sequence | MGSSHHHHHH SSGLVPRGSH MGSHM GWVDT HCLCYDFIIT PKSRPEPQWC EVQGLVDERP FLHYDCVNHK AKAFASLGKK VNVTKTWEEQ TETLRDVVDF LKGQLLDIQV ENLIPIEPLT LQARMSCEHE AHGHGRGSWQ FLFNGQKFLL FDSNNRKWTA LHPGAKKMTE KWEKNRDVTM FFQKISLGDC KMWLEEFLMY WEQMLDPTKP PSLAPG |
Target/Specificity | ULBP1 |
Format | Liquid |
Storage | -80°C; 0.5 mg/ml in 20 mM Tris-HCl buffer (pH 8.0) containing 0.15 M NaCl, 30% glycerol and 1 mM DTT. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ULBP1 is ligand for the NKG2D receptor, together with at least ULBP2 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. In CMV infected cells, ULBP1 interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface. Recombinant human ULBP1 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques.
References
Cosman D.,et al.Immunity 14:123-133(2001).
Onda H.,et al.Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
Radosavljevic M.,et al.Genomics 79:114-123(2002).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mungall A.J.,et al.Nature 425:805-811(2003).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.